Stack
Is the peptide identity interpretable at sequence or structure-string level?
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
Is this peptide linked to approved or named product context?
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
What safety, toxicity, or tolerability evidence is attached?
Can every measurement be reviewed in one cross-domain table?
Can the peptide identity be checked against reported names, sequence notation, and reference links?
Can this profile view be reproduced from structured records?
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
How stable is the peptide in biological matrices or protease systems?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Features are shown only when a reported notation or topology record supports them.
N-terminal pyroglutamate notation reported as pGlu.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Grouped composition is often more interpretable than a long amino-acid list.
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.
The same three research-facing layers are used across ADMETatlas.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 138 ng*h/mL | Comparable | AUC in overnight fasted C57BL/6N mouse at 1 mg/kg, ip · mouse | Route: ip · area under curve · AUC· AUC in overnight fasted C57BL/6N mouse at 1 mg/kg, ip · Exact ChE... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 157.1 nM | Comparable | Cmax in overnight fasted C57BL/6N mouse at 1 mg/kg, ip · mouse | Route: ip · max concentration · Cmax· Cmax in overnight fasted C57BL/6N mouse at 1 mg/kg, ip · Exact... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 1 hr 3600 seconds | Comparable | Tmax in overnight fasted C57BL/6N mouse at 1 mg/kg, ip · mouse | Route: ip · time to max concentration · Tmax· Tmax in overnight fasted C57BL/6N mouse at 1 mg/kg, ip... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 43-49 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · plasma | Leuprolide· Pharmacokinetics · plasma binding human plasma protein ranged percent · In vi... | Open |
| 2 | 43-49 % | Comparable | PepTherDia curated product PK field · plasma protein | Route: SC, IM, TOPICAL · 4 · Leuprolide · exact product name match · exact or normalized match | Open |
cell monolayer
barrier evidence
The identity reference does not expose a sequence string.
pGlu-HWSYlLRP
pGlu-HWSYlLRP
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.